AURKA and malignant peripheral nerve sheath tumor: Patel and colleagues identified Aurora kinase A (AURKA) as a candidate target for MPNST therapy by first modeling the disease in an animal model, identifying frequent amplification of AURKA in human tumours, and then treating MPNST cell-lines grown in vitro and as xenotransplants in vivo with an AURKA specific inhibitor, termed MLN8237 [5].